Exposure to wildfire smoke may increase the risk of developing several cancers, according to research presented at the AACR Annual Meeting 2026 by Shuguang Leng, MBBS, PhD, and Qizhen Wu, PhD, both of the...
FDA approves pembrolizumab and enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer regardless of cisplatin eligibility. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex)...
Cancer researchers—including Elizabeth M. Jaffee, MD, FAACR, of the Sidney Kimmel Cancer Center at Johns Hopkins; Robert H. Vonderheide, MD, DPhil, FAACR, of the Abramson Cancer Center of the University of Pennsylvania; Kornelia...
A double lung transplant could extend survival for certain people with advanced lung cancer, and LGBTQ+ people are less likely to receive some cancer screenings.
The FDA approved isatuximab-irfc as part of three different combination regimens for multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved isatuximab-irfc (Sarclisa Escena) for subcutaneous injection for three multiple myeloma indications:...
After surviving brain cancer, former competitive cyclist Chris Baccash dedicated his life to helping others. Baccash now uses his passion for cycling to make an impact, including by participating in the upcoming Philadelphia Cycling...
Researchers say the study’s findings could provide insight into the discrepancies in cancer outcomes between men and women. For years, it has been known that mortality rates for men are higher for many types...
At the AACR Special Conference on Advances in Malignant Lymphoma, Ronald Levy, MD, FAACR, of Stanford University, discussed how monoclonal antibodies transformed lymphoma treatment; Michel C. Nussenzweig, MD, PhD, of The Rockefeller University, explored...
Immunotherapy lowers risk for graft-versus-host disease, and women with cancer still lack crucial fertility preservation conversations.
The allogeneic regulatory T cell therapy was designed to improve HSCT outcomes in patients with hematological malignancies. The U.S. Food and Drug Administration (FDA) has approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More